Translational Research Center for CAM Therapy of Asthma

哮喘 CAM 治疗转化研究中心

• 批准号: 6952447
• 负责人: David B. Peden
• 金额: $ 119.94万
• 依托单位: UNIV OF NORTH CAROLINA CHAPEL HILL
• 依托单位国家: 美国
• 财政年份: 2004
• 资助国家: 美国
• 起止时间: 2004-09-30 至 2009-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6952447
• 关键词: alternative medicine; antioxidants; asthma; clinical research; respiratory disease /disorder therapy

The objective of this Translational Research Center for CAM therapy of Asthma is to identify antioxidant Complementary and Alternative Medicine therapies for application in asthma. To achieve this objective, we have assembled a team of investigators uniquely qualified for their roles in this project. Project 1 (Phase I Clinical Screening of CAM therapies for asthma, Drs. Peden, PPG PI, Alexis, Bromberg & Patel, UNC) will screen the effect of CAMs initially identified by Drs. Jiang and Ames (gamma tocopherol) or newly identified by Projects 2 & 3 in allergic asthmatic volunteers for Phase I proof of concept studies to determine in CAM therapies protect against endotoxin, O3, and allergen induced airway inflammation. Project 2 of the PPG (Preclinical evaluation of CAM therapies for asthma, Drs. Wagner & Harkema, MSU) will evaluate anti-inflammatory CAMs (or CAMs + traditional therpies) identified by Project 3 in allergen sensitized rodents determining if these CAMs, alone and in combination with traditional asthma therapies, blunt exacerbation of airway inflammation due to allergen, endotoxin and ozone (commonly encountered causes of asthma exacerbation). They will also carry out classic animal pathology and pharmacokinetic studies of CAMs. Project 3 of the PPG (Mechanistic Discovery of CAM Therapies for Asthma, Drs. Jiang, Illek and Ames at CHORI), will employ molecular and cellular techniques to examine the actions of tocopherols, ascorbate, polyphenols (genistein and resveratrol) on generation of oxygen radicals by MPO and EPO, mediator production via cyclo-oxygenase and lipoxygenase, and cellular activation via MAP kinases and NF-kB, and impact on epithelial cell physiology. A Biochemistry Core (Dr. Ames, core leader) will assess samples for products of tocopherol oxidation and oxidative burst and a Biomarker and Sample Repository Core (Dr. Patel, core leader) will provide support for cytokine and mediator assessment of samples and tissues for all projects. These studies will be coordinated via quarterly conference calls and semi-annual meetings of the project and core leaders rotated among the study sites. UNC will maintain a server accessable by all investigators to facilitate data sharing and planning of eventual human volunteer studies. Use of antioxidants is an under-investigated area and it is highly likely that these CAM agents will be effective in prevention of asthma exacerbation mediated by inflammatory processes.

该哮喘CAM治疗转化研究中心的目标是确定用于哮喘的抗氧化补充和替代医学疗法。为了实现这一目标，我们组建了一支具有独特资格的调查员队伍，他们在这个项目中扮演着独特的角色。项目一（ⅰ期哮喘辅助治疗药物临床筛选）Peden, PPG PI, Alexis, Bromberg & Patel， UNC)将筛选CAMs的影响。Jiang和Ames （γ -生育酚）或项目2和项目3在过敏性哮喘志愿者中新发现的，用于I期概念验证研究，以确定CAM疗法对内毒素，O3和过敏原诱导的气道炎症的保护作用。PPG项目2